Prevention of Ear Ulceration with Comfort Soft Plus® Nasal Oxygen Cannulas.
Mullen, “A Multidisciplinary Approach to the Prevention of Ear Ulcers” (Poster presented at 2014 WOCN Annual Conference). Trial of a soft nasal cannula (Westmed Comfort Soft Plus) “resulted in a decrease in the number of pressure ulcers on the designated unit of 100%.” ⬇︎PDF
Aerosol Delivery with VixOne™ Nebulizer and Circulaire® II Delivery Systems.
Gardenhire, “Improved Aerosol Delivery with a Conserver-Type Nebulizer System Powered By 6 Common Home Air Compressors” (Abstract for AARC Open Forum 2013). Optimal function of an SVN is dependent on proper driving pressure and flow, which apparently cannot be uniformly achieved by some air compressor and nebulizer combinations. The conserving effect of the Circulaire II Hybrid appears to compensate for marginally performing home air compressors and outperforms other SVNs tested. The Circulaire II Hybrid delivered from 1.6 to 2.8 times more medication than other nebulizers operated with the same air compressors, which was statistically significant. ⬇︎PDF
Grzeskowiak, “Evaluation of the Circulaire II Aerosol Drug Delivery System for Microbiological Contamination” (Poster at AARC Open Forum 2013). Clinical study, submitted to AARC 2013 Open Forum, in which Circulaire II and Circulaire II Hybrid nebulizers and reservoirs were cultured daily for up to 4 consecutive days while in use. The study concluded that, despite using minimal post-treatment practices, in 252 cultures, no significant organism growth was found in either the nebulizer or reservoir of the Circulaire II devices. These findings suggest that the valved conserver device may isolate the nebulizer and reservoir and protect them from contamination. ⬇︎PDF
“Understanding the Hess Paper.” This Westmed Clinical Education Bulletin dissects the classic Hess and colleagues paper wherein they compare functional performance of 17 different small volume nebulizers and determine that the Westmed VixOne is a top performer. ⬇︎PDF
Gardenhire, “An In Vitro Comparison of Dosimetric and Constant Output Nebulizers VixOne versus AeroEclipse” (Respir Care 2007). This bench study documents that the VixOne nebulizer outperforms the AeroEclipse II nebulizer in both continuous mode and breath-actuated mode with respect to inhaled mass, and shows that there is no statistically significant different between the two devices. ⬇︎PDF
Dennis, Test Report, “Circulaire II vs AeroEclipse II BAN” (SolAeroMed 2009). This bench study using the European Nebulizer Standards methodology demonstrates greater aerosol output and shorter delivery times for the VixOne nebulizer when compared to the AeroEclipse nebulizer at two different breathing patterns. ⬇︎PDF
McPeck, “In Vitro Inhaled Aerosol Comparison of a Conserver Nebulizer (Circulaire II) vs a Breath-Actuated nebulizer (AeroEclipse II)” (Respir Care 2010). This bench study demonstrated that the Circulaire II outperforms the AeroEclipse II with respect to greater Inhaled Mass and shorter treatment times measured during 4 different breathing patterns. ⬇︎PDF
Gardenhire, “In Vitro Comparison of Dosimetric Nebulizers” (Am J Respir Crit Care Med 2011). This bench study demonstrates that the Circulaire II outperforms the AeroEclipse II and delivers 53% more medication over a 5 minute treatment. These results were statistically significant. ⬇︎PDF
Gardenhire, “Circulaire II Hybrid with 6 Different Air Compressors” (Poster at North American Cystic Fibrosis Conference, 2013). ⬇︎PDF
“Protect the Patient; Protect the Caregiver with Circulaire.” This Westmed Clinical Education Bulletin reminds practitioners of the risks of aerosol therapy and discusses a recent study that proved that the Circulaire II system, with its unique “flapper valve” actually protects the nebulizer and the aerosol reservoir from becoming contaminated by exhaled patient droplets contained microorganisms. In addition, the CEB also discusses the importance of the integral exhalation filter in preventing exposure of healthcare workers to inhalable airborne medication particles and exhaled patient droplets that could cause illness, infection or untoward medication reactions. ⬇︎PDF
Grzeskowiak, “Adding Value to Aerosol Therapy.” (RT Magazine, March 2014). ⬇︎PDF